Indian drug makers are currently increasing their focus on disease areas and segments (including pain/inflammation and autoimmune diseases). Based on the relatively weak barriers to entering the generics business, price competition has inevitably been decreasing margins. Therefore, companies are hoping to face softer competition in these niche markets and consequently, enjoy greater margins. We are also beginning to see more interest in the development of novel drugs among domestic companies. Going forward, Indian companies need to tap into the international market, particularly other emerging markets in Latin America and Eastern Europe, to take advantage of the rapidly increasing insurance coverage and economic growth in these regions. In sync with that Qualtra Pharma is also working with manufacturing partners in product development ,BE studies and strong inclination to invest in R & D Future focus with our manufacturing partners.